Sanofi-aventis has posted a net income of EUR1.66bn for the third quarter 2010, compared to EUR1.53bn for the comparable period in 2009.
Operating income was EUR1.71bn, compared to EUR1.76bn for the comparable period in 2009.
Sanofi-aventis has posted net sales of EUR22.99bn, compared to EUR21.95bn for the year ago period.
For the nine months ended 30 September 2010 net income was EUR5.23bn, compared to EUR4.4bn for the year ago period.
Operating income was EUR5.72bn, compared to EUR5.04bn for the year ago period.
Sanofi-aventis CEO Christopher Viehbacher said that the third quarter was marked by the success of the Jevtana launch in the US, by positive Phase III data for Lixisenatide and Teriflunomide but also by the entry of a generic of Lovenox in the US.
"Tight cost control and good performance of growth platforms have allowed the Group to slightly raise its guidance for 2010," Viehbacher said.